Literature DB >> 30024271

A viewpoint on rational and irrational fixed-drug combinations.

Barbara Błaszczyk1, Barbara Miziak2, Piotr Czuczwar2,3, Ewa Wierzchowska-Cioch2,4, Ryszard Pluta5, Stanisław J Czuczwar2,6.   

Abstract

INTRODUCTION: Considering that there are around 30% of patients with epilepsy resistant to monotherapy, the use of synergistic combinations of antiepileptic drugs is of particular importance. This review shows most beneficial as well as irrational combined treatments both from an experimental and clinical point of view. Areas covered: Preferably, experimental data derived from studies evaluating synergy, additivity, or antagonism by relevant methods, in terms of anticonvulsant or neurotoxic effects and pharmacokinetic data have been considered. Although there have been no randomized clinical trials on this issue, the clinical data have been analyzed from studies on considerable numbers of patients. Case-report studies have been not considered. Expert commentary: The experimental data provide a strong support that co-administration of lamotrigine with carbamazepine is negative, considering the anticonvulsant and neurotoxic effects. Clinical reports do not entirely support this conclusion. Other experimentally documented negative combinations comprise lamotrigineoxcarbazepine and oxcarbazepinephenytoin. From the experimental and clinical point of view, a combination of lamotriginevalproate may deserve recommendation. Other most positive experimental and clinical combinations include carbamazepine+valproate, phenytoin+phenobarbital, carbamazepine+gabapentin, carbamazepine+topiramate, levetiracetam+valproate, levetiracetam+carbamazepine. Certainly, experimental data have some limitations (non-epileptic animals, acute administration of antiepileptic drugs) so all experimental recommendations need a careful clinical evaluation.

Entities:  

Keywords:  Antiepileptic drugs; anticonvulsant; drug combinations; epilepsy; isobolography; neurotoxicity; seizures

Mesh:

Substances:

Year:  2018        PMID: 30024271     DOI: 10.1080/17512433.2018.1500895

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN: 1751-2433            Impact factor:   5.045


  6 in total

Review 1.  Treatment of Juvenile Myoclonic Epilepsy in Patients of Child-Bearing Potential.

Authors:  Anna Serafini; Elizabeth Gerard; Pierre Genton; Arielle Crespel; Philippe Gelisse
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

2.  Polygonogram and isobolographic analysis of interactions between various novel antiepileptic drugs in the 6-Hz corneal stimulation-induced seizure model in mice.

Authors:  Jarogniew J Luszczki; Anna Panasiuk; Mirosław Zagaja; Sławomir Karwan; Hubert Bojar; Zbigniew Plewa; Magdalena Florek-Łuszczki
Journal:  PLoS One       Date:  2020-06-01       Impact factor: 3.240

Review 3.  Epilepsy in Pregnancy-Management Principles and Focus on Valproate.

Authors:  Barbara Błaszczyk; Barbara Miziak; Ryszard Pluta; Stanisław J Czuczwar
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

Review 4.  Anti-Epileptogenic Effects of Antiepileptic Drugs.

Authors:  Barbara Miziak; Agnieszka Konarzewska; Marzena Ułamek-Kozioł; Monika Dudra-Jastrzębska; Ryszard Pluta; Stanisław J Czuczwar
Journal:  Int J Mol Sci       Date:  2020-03-28       Impact factor: 5.923

5.  Neurosteroids and Seizure Activity.

Authors:  Barbara Miziak; Magdalena Chrościńska-Krawczyk; Stanisław J Czuczwar
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-30       Impact factor: 5.555

Review 6.  The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond.

Authors:  Wolfgang Löscher; Pavel Klein
Journal:  CNS Drugs       Date:  2021-06-18       Impact factor: 5.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.